| Mechanisms of suppression of cell growth by dual inhibition of ALK and MeK in ALK-positive non-small cell lung cancer N Shrestha, M Nimick, P Dass, RJ Rosengren, JC Ashton Scientific Reports 9 (1), 1-12, 2019 | 23 | 2019 |
| δ-Catenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer N Shrestha, H Shrestha, T Ryu, H Kim, S Simkhada, YC Cho, SY Park, ... Molecules and cells 41 (4), 320, 2018 | 16 | 2018 |
| The effect of metformin in EML4-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models AR Bland, N Shrestha, RL Bower, RJ Rosengren, JC Ashton Biochemical Pharmacology 183, 114345, 2021 | 12 | 2021 |
| Investigation of the molecular mechanism of δ-catenin ubiquitination: Implication of β-TrCP-1 as a potential E3 ligase H Shrestha, T Yuan, Y He, PG Moon, N Shrestha, T Ryu, SY Park, YC Cho, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1863 (9), 2311-2321, 2016 | 11 | 2016 |
| Does the mouse tail vein injection method provide a good model of lung cancer? N Shrestha, Z Lateef, O Martey, AR Bland, M Nimick, R Rosengren, ... F1000Research 8, 2019 | 9 | 2019 |
| Interaction of EGFR to δ-catenin leads to δ-catenin phosphorylation and enhances EGFR signaling Y He, T Ryu, N Shrestha, T Yuan, H Kim, H Shrestha, YC Cho, YW Seo, ... Scientific reports 6, 21207, 2016 | 9 | 2016 |
| ALK-positive non-small cell lung cancer; potential combination drug treatments. S Nensi, J Ashton Current Cancer Drug Targets, 2021 | 7 | 2021 |
| Does Crizotinib Auto-Inhibit CYP3A in vivo? AR Bland, N Shrestha, RJ Rosengren, JC Ashton Pharmacology 105 (11-12), 715-718, 2020 | 5 | 2020 |
| Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance. AR Bland, N Shrestha, M Berry, C Wilson, JC Ashton Current Cancer Drug Targets, 2022 | 1 | 2022 |
| Combination of ALK and MEK inhibitors for the treatment of ALK-positive non-small cell lung cancer N Shrestha University of Otago, 2020 | | 2020 |
| Inhibition of MEK alone and in combination with ALK inhibition suppresses tumor growth in a mouse model of ALK positive lung cancer. N Shrestha, AR Bland, RL Bower, R Rosengren, J Ashton Journal of Pharmacology and Experimental Therapeutics, 2020 | | 2020 |
| δ-catenin increases the stability of EGFR by decreasing c-Cbl interaction and enhances EGFR/Erk1/2 signaling in prostate cancer S Nensi, HE Yongfeng, S Hridaya, RYU Taeyong, KIM Kwonseop 추계총회 및 학술대회, 93-93, 2015 | | 2015 |
